Arcutis Biotherapeutics, Inc. logo ARQT - Arcutis Biotherapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 10
HOLD 2
SELL 0
STRONG
SELL
0
| PRICE TARGET: $35.50 DETAILS
HIGH: $37.00
LOW: $34.00
MEDIAN: $35.50
CONSENSUS: $35.50
UPSIDE: 70.18%

About Arcutis Biotherapeutics, Inc. (https://www.arcutis.com)

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Key Executives

NAME TITLE DOB SALARY
Todd Franklin Watanabe President, Chief Executive Officer & Director 1968 $1,306,917 USD
L. Todd Edwards Executive Vice President & Chief Commercial Officer 1964 $897,205 USD
Patrick E. Burnett Executive Vice President & Chief Medical Officer 1972 $883,376 USD
Masaru Matsuda Executive VP, Chief Legal Officer & Corporate Secretary 1971 $787,699 USD
Latha Vairavan Senior Vice President & Chief Financial Officer 1978 $644,904 USD
Bethany Dudek Chief Technical Officer $584,551 USD
Bhaskar Chaudhuri Co-Founder & Director Emeritus 1955 $60,054 USD
Aleen Hosdaghian Vice President of Marketing
Amanda Sheldon Head of Corporate Communications
Brian Schoelkopf Head of Investor Relations
Douglas DiRuggiero DMSC Advanced Practitioner
Jeff Kiekhofer VP & Controller
Rajvir Madan Chief Digital & Technology Officer
Steve Arias Vice President of Compliance & Privacy

Company Peers

Peer analysis pending, check back in 1-2 minutes.